2021 MAGNIMS-CMSC-NAIMS多发性硬化MRI应用共识建议
该2021年共识整合了MAGNIMS、CMSC和NAIMS的建议,将2015/2016年指南更新为多发性硬化MRI使用的新推荐。基于2017年McDonald诊断标准修订、钆对比剂安全性担忧和脊髓MRI价值等进展,共识推荐了MRI采集方案变更(如3D-FLAIR作为核心脑序列)和钆对比剂的审慎使用,并扩展到儿童、妊娠及产后患者。
要点
- 推荐3D-FLAIR作为核心脑脉冲序列,以提高诊断准确性和监测新病灶。
- 针对特定临床目的,审慎使用钆基对比剂。
- MRI推荐扩展至儿童、妊娠和产后多发性硬化患者。
核心结论
- 2021年共识更新了多发性硬化MRI使用建议,整合三个机构推荐以改善诊断、预后和监测。
研究设计与样本
- 制定机构为MAGNIMS、CMSC和NAIMS,方法为基于研究进展修订既往指南并形成共识推荐。
主要发现
- 2017年McDonald诊断标准修订、钆对比剂安全性新担忧及脊髓MRI价值等进展提示MRI角色变化。
- 推荐强调3D-FLAIR作为核心脑序列以提高诊断准确性和识别新病灶以监测疗效。
关键数值与推荐
- 推荐3D-FLAIR作为核心脑脉冲序列以提高诊断准确性和监测治疗有效性。
- 提供针对特定临床目的审慎使用钆基对比剂的建议。
- 建议扩展至儿童、妊娠和产后多发性硬化患者的MRI使用。
临床怎么用
- 临床应采用3D-FLAIR作为核心脑序列进行多发性硬化诊断和监测。
- 根据特定临床目的审慎使用钆对比剂,并关注儿童、妊娠及产后患者的MRI应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple sclerosis made an important step towards appropriate use of MRI in routine clinical practice. Since their promulgation, there have been substantial relevant advances in knowledge, including the 2017 revisions of the McDonald diagnostic criteria, renewed safety concerns regarding intravenous gadolinium-based contrast agents, and the value of spinal cord MRI for diagnostic, prognostic, and monitoring purposes. These developments suggest a changing role of MRI for the management of patients with multiple sclerosis. This 2021 revision of the previous guidelines on MRI use for patients with multiple sclerosis merges recommendations from the Magnetic Resonance Imaging in Multiple Sclerosis study group, Consortium of Multiple Sclerosis Centres, and North American Imaging in Multiple Sclerosis Cooperative, and translates research findings into clinical practice to improve the use of MRI for diagnosis, prognosis, and monitoring of individuals with multiple sclerosis. We recommend changes in MRI acquisition protocols, such as emphasising the value of three dimensional-fluid-attenuated inversion recovery as the core brain pulse sequence to improve diagnostic accuracy and ability to identify new lesions to monitor treatment effectiveness, and we provide recommendations for the judicious use of gadolinium-based contrast agents for specific clinical purposes. Additionally, we extend the recommendations to the use of MRI in patients with multiple sclerosis in childhood, during pregnancy, and in the post-partum period. Finally, we discuss promising MRI approaches that might deserve introduction into clinical practice in the near future.
引用
- Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021. PMID: 34139157. doi:10.1016/S1474-4422(21)00095-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。